



Orion Capital Markets Day 2023

Helsinki 25 May 2023

Disclaimer

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

All the figures in this presentation have been rounded, which is why the total sums of individual figures may differ from the total sums shown.

This presentation is for investor use only. Not to be used for other purposes.



The road is open for growth

Liisa Hurme, President & CEO



Disclaimer

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

All the figures in this presentation have been rounded, which is why the total sums of individual figures may differ from the total sums shown.

This presentation is for investor use only. Not to be used for other purposes.

First 100+ days as a CEO of Orion



President & CEO 11/2022 →

Education: Ph. D. (Biochemistry)

ORION CAREER

2019-2022 SVP, Global Operations
 2014-2022 Chairman of the Board of Fermion Oy
 2014-2018 SVP, Specialty Products
 2008-2013 SVP, Proprietary Products
 2005-2007 Head of Urology and Oncology business
 2004-2005 Program Leader of pharmaceutical development projects for Hormonal and Urological therapies
 2002-2004 Portfolio Manager
 2001-2002 Project Manager
 1999-2001 Researcher and Project Manager, Hormonal therapies

KEY REFLECTIONS



New organisation and divisional structure



Dedicated and committed personnel




World-class partners dedicated and committed




Solid growth drivers

More than ten years of patent cliffs – still going strong



* 2022 w/o EUR 228 million milestone


- Entacapone products
- Simdax®
- Easyhaler®
- Dexmedetomidine for human use
- Rest of the portfolio
- Nubeqa®




* 2022 w/o EUR 208 million impact from a milestone

- Operating profit

Steady development in dividends at all times



A Nordic company with global reach has potential to grow



● ● ● Average annual growth 2021-2025

Europe, TOP 5 = Germany, France, Italy, United Kingdom, Spain

◐ Market share from total global market in 2023

Seeking growth in ever more complex environment

Megatrends



Growing and ageing population



Data utilisation and new technologies



Sustainability

Partnerships



Global supply chains



Compliance



ESG requirements



Pricing pressure

Regulatory environment

Strategy and mission

Strategic targets

- Growing more rapidly than the growth in the market
- Providing patients with new innovative and cost-effective drugs and treatments
- Working together to benefit the customer
- Continuous improvement of performance in sustainability
- Strong development of profitability

Mission to build-well being

Operating environment

- Ageing of population
- Increasing healthcare cost burden
- Advances in science
- Increased personal responsibility for own health and pets' health
- Sustainability

- Quality and safety
- Competitive and dynamic product portfolio
- Strong corporate culture of working together
- Building strong partnerships
- Productivity and flexibility

Preconditions for strategic success

New organisational structure allows divisions to engage customers in a more targeted way



Innovative Medicines



Fermion




Animal Health



Branded Products



Generics and Consumer Health



²Split w/o ODM-208 upfront payment

Growth drivers for Orion



* Development phase molecule – requires success in clinical development and regulatory approval

